GT201000088A - 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa - Google Patents
2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasaInfo
- Publication number
- GT201000088A GT201000088A GT201000088A GT201000088A GT201000088A GT 201000088 A GT201000088 A GT 201000088A GT 201000088 A GT201000088 A GT 201000088A GT 201000088 A GT201000088 A GT 201000088A GT 201000088 A GT201000088 A GT 201000088A
- Authority
- GT
- Guatemala
- Prior art keywords
- desoxitetrahydrouridins
- desaminasa
- citidine
- fluoro
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- UCKYOOZPSJFJIZ-FMDGEEDCSA-N (4r)-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 UCKYOOZPSJFJIZ-FMDGEEDCSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN PROVEE DETERMINADOS COMPUESTOS DERIVADOS DE TETRAHIDROURIDINA, COMPOSICIONES FARMACÉUTICAS Y KITS QUE COMPRENDEN TALES COMPUESTOS Y MÉTODOS DE PREPARACIÓN Y USO DE TALES COMPUESTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98039707P | 2007-10-16 | 2007-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201000088A true GT201000088A (es) | 2012-03-13 |
Family
ID=40251685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201000088A GT201000088A (es) | 2007-10-16 | 2010-04-12 | 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa |
Country Status (39)
Country | Link |
---|---|
US (4) | US8268800B2 (es) |
EP (2) | EP2447272B1 (es) |
JP (2) | JP5496899B2 (es) |
KR (1) | KR101543049B1 (es) |
CN (1) | CN101827856B (es) |
AT (1) | ATE548374T1 (es) |
BR (1) | BRPI0818672B8 (es) |
CA (1) | CA2702274C (es) |
CO (1) | CO6270330A2 (es) |
CR (1) | CR11427A (es) |
CY (3) | CY1112781T1 (es) |
DK (1) | DK2207786T3 (es) |
EA (1) | EA018757B1 (es) |
EC (1) | ECSP10010095A (es) |
ES (2) | ES2384011T3 (es) |
FI (2) | FIC20230039I1 (es) |
FR (2) | FR23C1051I1 (es) |
GT (1) | GT201000088A (es) |
HK (1) | HK1146410A1 (es) |
HR (1) | HRP20120419T1 (es) |
HU (2) | HUS2300045I1 (es) |
IL (1) | IL204732A (es) |
JO (1) | JO2778B1 (es) |
ME (1) | ME00997B (es) |
MX (1) | MX2010004109A (es) |
MY (1) | MY147970A (es) |
NI (1) | NI201000055A (es) |
NL (1) | NL301256I2 (es) |
NO (2) | NO2023047I1 (es) |
NZ (1) | NZ584229A (es) |
PL (1) | PL2207786T3 (es) |
PT (1) | PT2207786E (es) |
RS (1) | RS52323B (es) |
SA (1) | SA08290661B1 (es) |
SI (1) | SI2207786T1 (es) |
TW (1) | TWI445539B (es) |
UA (1) | UA99476C2 (es) |
WO (1) | WO2009052287A1 (es) |
ZA (1) | ZA201002178B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
MX363023B (es) | 2008-05-15 | 2019-03-05 | Celgene Corp | Formulaciones orales de analogos de citidina y metodos para usar los mismos. |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
TW201031675A (en) * | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
TWI503121B (zh) * | 2009-04-06 | 2015-10-11 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
EP2416781B1 (en) * | 2009-04-06 | 2017-03-08 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
AU2010234637B2 (en) * | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
UY33311A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
MX363205B (es) * | 2013-10-29 | 2019-03-13 | Otsuka Pharma Co Ltd | Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas. |
KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
ES2940302T3 (es) | 2014-08-22 | 2023-05-05 | Celgene Corp | Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos |
EP3383406B1 (en) | 2015-12-03 | 2021-10-20 | Epidestiny, Inc. | Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof |
WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
KR20200118827A (ko) | 2018-02-02 | 2020-10-16 | 마베릭스 온콜로지, 잉크. | 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트 |
US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
JP7433662B2 (ja) * | 2018-10-19 | 2024-02-20 | インターオリゴ・コーポレイション | 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物 |
KR102280330B1 (ko) * | 2018-10-19 | 2021-07-21 | 인터올리고 주식회사 | 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물 |
KR20220078619A (ko) | 2019-10-08 | 2022-06-10 | 오츠카 세이야쿠 가부시키가이샤 | 고순도의 2'-데옥시-2',2'-디플루오로테트라히드로우리딘 및 그의 제조 방법 |
KR20220145815A (ko) * | 2020-02-25 | 2022-10-31 | 오츠카 세이야쿠 가부시키가이샤 | 조합 데시타빈 및 세다주리딘 고체 경구 투여 형태 |
AU2022244240A1 (en) * | 2021-03-26 | 2023-10-05 | The Cleveland Clinic Foundation | Treatment of rna virus infection with a cytidine deaminase inhibitor |
US20240279266A1 (en) * | 2021-05-29 | 2024-08-22 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds |
KR20240108406A (ko) | 2021-10-19 | 2024-07-09 | 아키라바이오, 인크. | 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도 |
WO2023076332A1 (en) * | 2021-11-01 | 2023-05-04 | St. John's University | Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor |
US20230271996A1 (en) * | 2021-12-25 | 2023-08-31 | Scinopharm Taiwan, Ltd. | Process for preparing cedazuridine |
TW202410893A (zh) | 2022-08-31 | 2024-03-16 | 日商大塚製藥股份有限公司 | 用於治療t細胞淋巴瘤之結合治療 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017606A (en) * | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
US4210638A (en) * | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
US4275057A (en) | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE3481172D1 (de) | 1983-10-26 | 1990-03-08 | Sheldon B Greer | Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung. |
IL77133A (en) | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US4965374A (en) | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
CA2086233C (en) | 1991-04-23 | 1995-10-17 | Wendy Oglevee-O'donovan | In vitro leaf petiole multiplication of pelargoniums |
FR2682112B1 (fr) | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5594124A (en) | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
WO1994019362A1 (en) | 1993-02-23 | 1994-09-01 | City Of Hope | 4-ethoxy 5-fluoro 2'deoxyuridine |
WO1994026761A1 (en) | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
US5637688A (en) | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
AU5300396A (en) * | 1995-03-01 | 1996-09-18 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
US5760208A (en) | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
DE60030842T2 (de) | 1999-03-01 | 2007-05-10 | Halogenetics Inc., Aventura | VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN |
US6933287B1 (en) | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
EP1207783A1 (en) | 1999-08-26 | 2002-05-29 | Aortech International PLC | Improvements relating to catheter positioning |
US6462191B1 (en) | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
US7125983B2 (en) | 2000-11-29 | 2006-10-24 | Mitsui Chemicals, Inc. | L-nucleic acid derivatives and process for the synthesis thereof |
JP4458746B2 (ja) | 2001-01-16 | 2010-04-28 | グラクソ グループ リミテッド | 癌の治療方法 |
WO2002094844A2 (en) | 2001-05-18 | 2002-11-28 | Rakesh Kumar | Antiviral nucleosides |
US8207142B2 (en) * | 2001-07-31 | 2012-06-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
AU2003217402A1 (en) | 2002-02-14 | 2003-09-04 | Pharmasset Inc | Modified fluorinated nucleoside analogues |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
AU2003278904A1 (en) | 2002-09-24 | 2004-04-19 | Kornis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
US8158770B2 (en) | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
TW200606159A (en) | 2004-07-30 | 2006-02-16 | Pharmaessentia Corp | Stereoselective synthesis of β-nucleosides |
CA2586687A1 (en) | 2004-12-08 | 2006-06-15 | Sicor Inc. | Difluoronucleosides and process for preparation thereof |
WO2008085611A2 (en) * | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
EP2416781B1 (en) | 2009-04-06 | 2017-03-08 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
TWI503121B (zh) | 2009-04-06 | 2015-10-11 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
AU2010234637B2 (en) | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer |
-
2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active IP Right Grant
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en active Application Filing
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
-
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
-
2011
- 2011-01-20 HK HK11100565.2A patent/HK1146410A1/xx unknown
-
2012
- 2012-05-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
-
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
-
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
-
2023
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-26 FR FR23C1051C patent/FR23C1051I1/fr active Active
- 2023-12-26 FR FR23C1052C patent/FR23C1052I1/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201000088A (es) | 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
AR061246A1 (es) | Anticuerpos anti- dill4 y metodos que los usan | |
CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
ECSP099619A (es) | Anticuerpos anti-robo4 y sus usos | |
CO2018000668A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
CR20150088A (es) | Anticuerpos anti-notch1 nrr | |
BR112013004341A2 (pt) | composições pesticidas | |
CR11861A (es) | Compuestos organicos | |
HN2008000179A (es) | Compuestos triciclicos,composiciones y procedimientos | |
ECSP077316A (es) | Compuestos imidazo-3-il-amina bicíclicos sustituidos | |
CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
CR20150315A (es) | Biocontrol de nemátodos fitoparásitos mediante paecilomyces | |
CR20110497A (es) | Nuevos anticuerpos anti-alfa5beta1 y sus usos | |
AR059096A1 (es) | Anticuerpos anti- efrina -b2 y metodos que usan estos | |
PA8792401A1 (es) | Fenilendiaminas | |
HK1133642A1 (en) | Azaadamantane ester and carbamate derivatives and methods of use thereof | |
ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
ECSP11011486A (es) | Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente | |
BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
BR112013000840A2 (pt) | método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial. | |
GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia |